Shore Capital Reiterates Hold Rating for Diploma (LON:DPLM)

Diploma (LON:DPLM)‘s stock had its “hold” rating restated by research analysts at Shore Capital in a report issued on Thursday, MarketBeat reports. They presently have a GBX 5,100 ($68.46) price objective on the stock. Shore Capital’s target price would indicate a potential downside of 1.92% from the company’s previous close.

Diploma Trading Down 0.4%

Shares of DPLM stock opened at GBX 5,200 ($69.80) on Thursday. The business’s fifty day moving average price is GBX 4,734.15 and its 200 day moving average price is GBX 4,369.79. Diploma has a 1-year low of GBX 3,532 ($47.41) and a 1-year high of GBX 5,625 ($75.50). The firm has a market capitalization of £6.94 billion, a PE ratio of 59.77, a P/E/G ratio of 2.82 and a beta of 0.75. The company has a debt-to-equity ratio of 62.17, a current ratio of 2.17 and a quick ratio of 0.80.

Diploma (LON:DPLM) last posted its earnings results on Wednesday, May 21st. The company reported GBX 80.20 ($1.08) EPS for the quarter. Diploma had a return on equity of 13.18% and a net margin of 9.25%. As a group, sell-side analysts forecast that Diploma will post 163.7995512 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Katie Bickerstaffe bought 44 shares of the firm’s stock in a transaction on Wednesday, May 21st. The shares were bought at an average cost of GBX 4,867 ($65.33) per share, for a total transaction of £2,141.48 ($2,874.47). Insiders acquired 96 shares of company stock worth $473,173 in the last quarter. 0.52% of the stock is currently owned by insiders.

About Diploma

Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.